AdAlta (ASX:1AD) Other Income (Expense) : A$3.56 Mil (TTM As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is AdAlta Other Income (Expense)?

AdAlta's other income expense for the AdAlta's pretax income for the six months ended in Dec. 2023 was A$1.11 Mil. Its other income expense for the trailing twelve months (TTM) ended in Dec. 2023 was A$3.56 Mil.

AdAlta Other Income (Expense) Historical Data

The historical data trend for AdAlta's Other Income (Expense) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AdAlta Other Income (Expense) Chart

AdAlta Annual Data

Trend

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Other Income (Expense)

Get a 7-Day Free Trial

3.56

3.14

3.02

1.81

3.55

AdAlta Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Other Income (Expense)	Get a 7-Day Free Trial										0.74	1.08	1.11	2.45	1.11

AdAlta Other Income (Expense) Calculation

Other income expense includes minority interest. Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company.

Other Income (Expense) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$3.56 Mil.

AdAlta (ASX:1AD) Other Income (Expense) Explanation

Minority interest is reported on the consolidated income statement as a share of profit belonging to minority shareholders.

AdAlta (ASX:1AD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AdAlta Ltd (ASX:1AD) » Definitions » Other Income (Expense)

Comparable Companies

Traded in Other Exchanges

N/A

Address

2 Park Drive, Unit 15, Bundoora, VIC, AUS, 3083

Website

https://www.adalta.com.au

AdAlta Ltd is engaged in drug discovery and development company developing protein therapeutics, known as i-bodies, for treating a wide range of human diseases. The i-body candidate, AD-214, is being developed for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases, for which current therapies are sub-optimal. Its pipeline includes Fibrosis, and CAR-T cancer therapeutics.

AdAlta (ASX:1AD) Headlines

No Headlines